Introduction
============

Management of motor fluctuations and dyskinesias is still a major challenge in the long-term treatment of patients with Parkinson's disease (PD) as they affect daily life activities and in turn quality of life of patients and caregivers. Symptoms associated with the "off phase" not only include akinesia, rigidity, and tremor, but also depression, anxiety or even panic attacks ([@b21]). In the advanced stages of the disease both motor and non-motor fluctuations are present ([@b33]).

Dyskinesias are classified according to their temporal profile after drug administration, namely peak-dose dyskinesias (mainly choreic movements), biphasic dyskinesias, onset and end-of-dose (mainly dystonic and ballic movements), and finally "off"-period dyskinesias (dystonic movements) ([@b13]).

In general motor fluctuations and dyskinesia develop in about 10% of patients per year after starting levodopa treatment, reaching almost 100% of patients after 10 years' treatment (Marsden and Parkes 1997; [@b53]). The DATATOP study reported high rates of motor fluctuations and dyskinesias ([@b40]), but this might be related to direct patient observation during the trial phase ([@b20]).

Recently, a retrospective analysis of the CALM-PD study reported an incidence of motor fluctuations within a range from 12% to 60%, and an incidence of dyskinesias from 8% to 64%, after 4--6 years of levodopa therapy ([@b18]).

Factors involved in the development of motor complications are not completely elucidated yet. Patients with motor fluctuations (wearing off, on-off phenomenon) may show akinetic-rigid onset, longer disease and treatment duration, higher intake of levodopa dose per day (\>300 mg/day), and occasionally longer time latency since diagnosis. They also show greater disability according to the Schwab-England scale and disease severity. The finding of a family history of parkinsonism is also frequent, suggests that positive genetic may lead to greater propensity to development of motor complications. Similarly patients with dyskinesias tend to present higher Hoehn and Yahr score and longer treatment duration, while association with levodopa daily dose is less consistent. Gender as well as genetic factors related to dopamine D2 receptor gene may also play an important role and contribute to development of peak-dose dyskinesia in women ([@b48]; [@b57]).

Although fluctuations in response to levodopa are typically defined by changes in motor signs, autonomic and psychological fluctuations may also occur.

Non-motor fluctuations (NMF) are extremely disabling for PD patients; they affect activity of daily living and quality of life and have recently received growing attention by movement disorders experts. Similar to motor fluctuation, non-motor fluctuations also tend to increase with disease progression, and are more disabling in younger patients ([@b47]; [@b56]).

Non-motor fluctuations may involve cognitive, psychiatric, sensory/pain, and autonomic domains ([@b10], [@b9]).

Assessment of frequency and disability caused by NMF was evaluated in 50 PD patients by the administration of a specific questionnaire ([@b27]). All patients showed at least one type of NMF, mostly associated with the "off" state. The most represented were anxiety (66%), drenching sweats (64%), slowness of thinking (58%), fatigue (56%), and akathisia (54%). All NMF contributed to the worsening motor disability, and especially fluctuations linked to autonomic functions were also related to levodopa treatment.

Some degree of sadness and mood switching is also frequently reported during "on-off" periods ([@b28]). Mood fluctuations may occur more frequently in patients with involvement of cortical or mesolimbic areas ([@b10]).

The stringent relationship between levodopa response and non-motor fluctuations is also supported by the occurrence of "off period" depressive symptoms after discontinuation of levodopa intravenous infusion ([@b26], [@b27]).

Finally, a PET study in a small number of PD patients showed that rCBF response to levodopa in medial frontal gyrus and posterior cingulated cortex (PCC), was different between mood fluctuators and controls ([@b4]). As PCC is strongly linked to emotions and mood, and it is known to modulate dopaminergic innervations of caudate nucleus, anterior cingulated cortex, and orbital frontex, the authors speculate that mood fluctuations in PD might be related to dysfunction in levodopa responsiveness.

Levodopa administration and response to levodopa: addressing indication to starting therapy
===========================================================================================

Levodopa is the most effective treatment of PD cardinal symptoms (rigidity, akinesia, tremor, postural instability) ([@b45]). The onset of effect is rapid, and most clinical trial results suggest that initiating treatment provides superior motor and functional control compared with other dopaminergic substances. Levodopa is generally well tolerated, with lower incidence of gastrointestinal and neuropsychiatric adverse events ([@b19]).

The mechanism of action is not simply characterized by a central conversion of levodopa to dopamine at surviving dopaminergic terminals, but also by a neuromodulation ([@b38]), and likely internalization of D1 receptors, as demonstrated in rats ([@b29]). Moreover, increasing motor fluctuations in the afternoon and evening in patients during long-term levodopa therapy may not relate to the pharmacokinetics of the drug but express tolerance to repeated doses of levodopa ([@b5]).

Administration of levodopa is associated with negative perception on motor complications risk, leading to a delay in initiating treatment that has been defined as "levodopa phobia".

The relevance of patient age at disease onset for starting levodopa therapy is still debated and current guidelines have not yet properly assessed this issue. The problem of starting levodopa treatment early arises in younger patients with mild motor dysfunction, in consideration of life expectancy and disease progression. Because of its greater efficacy than dopamine agonists, levodopa is recommended as first-line agent always in case of a rapid and sustained worsening of motor symptoms, regardless of age ([@b35]).

The declining efficacy of levodopa therapy surely recognizes, at least in part, a progression of the disease, and this must be considered especially in terms of expectations on quality of life.

Some hypotheses around the mechanisms by which response fluctuations may occur with levodopa have been conceived ([@b53]):

1.  presynaptic neuronal degeneration leading to insufficient buffering of released levodopa, which could be mainly related to the "wearing off" phenomenon.

2.  postsynaptic changes in dopamine receptor sensitivity and number, partially caused by presynaptic changes , which could be related to the unpredictable fluctuations.

3.  pharmacokinetic and pharmacodynamic influence of other dopaminergic agents or non-pharmacological agents (such as food).

Clinical response to levodopa can identify at least three different mechanisms
------------------------------------------------------------------------------

The best known is the short-duration response (SDR), measured in minutes to hours, with a steep concentration -- response relationship such that the response appears "all or nothing". The duration of the effect is dose-responsive. During chronic therapy, the SDR becomes shorter, as does the onset to effect, whereas the magnitude of the response becomes larger, probably because of a sensitization phenomenon ([@b31]). With regard to tolerance, experiments on levodopa holidays of 2--4 days, demonstrated that post-holiday infusion produced a longer response than did pre-holiday infusion, as measured by tapping and walking speed, tremor, and dyskinesias. The prolongation of the response was greater in patients receiving higher daily doses of levodopa ([@b32]).

The long-duration response (LDR) results from repetitive administrations of levodopa and develops over days or weeks after starting treatment ([@b58]). It is independent of single intakes of levodopa which, in turn, determine SDRs associated with motor fluctuations and dyskinesia ([@b59]). On the contrary, the presence of the LDR may ensure a stable clinical benefit and its disappearance may be relevant for the development of a fluctuating condition ([@b61]). The LDR is more evident in early PD stages, but it could be induced also in more advanced stages ([@b43]), by modulating the inter-dose intervals and the size of each dose ([@b60]). The rate of decay is proportional to the severity of illness, and therefore it might be related to the dopamine storage capacity of surviving nerve terminals. Finally in advanced stages of the disease, we can also identify a negative response (super-off), measured in minutes to hours, and consisting of motor function worsening below the basal level.

Strategies to widen levodopa therapeutic window
===============================================

The management of motor and non-motor fluctuations aims at prolonging the effect of dopaminergic stimulation possibly reducing total levodopa load. The effects of a single dose of levodopa may shorten to less than 2--3 hours in advanced patients. Early symptoms of "wearing off" may be improved by redistributing levodopa dosing during the day and shortening the interval between doses ([@b55]). Alternatively, as modifications of LDR may underline motor fluctuations ([@b58], [@b61]), strategies that involve increasing single levodopa dose rather than number of administrations might also be beneficial, if dyskinesia does not worsen ([@b60]).

There are different strategies aimed at stimulating dopamine receptors in a more continuous, less pulsatile manner, to slow levodopa metabolism, interacting at different levels, and consequently providing a more sustained central effect.

Continuous intraduodenal infusion produces stable levodopa plasma levels resulting in few off periods and dyskinesia as well as improved quality of life, but it can be applied only in limited cases ([@b2]).

Slow-release preparations of levodopa (Sinemet CR^®^, Madopar HBS^®^), associated with peripheral dopa decarboxylase inhibitor (DDCI), may be helpful in smoothing out fluctuations, alleviating tremor and rigidity during the night, and morning akinesia as well. However, their absorption and effect is often erratic making their use in a clinical setting very limited.

The MAO-B inhibitors: effectiveness and rationale for use in clinical setting
-----------------------------------------------------------------------------

MAO-B inhibitors (selegiline, rasagiline), may be an alternative to levodopa in the early treatment ([@b16]). Although no medication has been proven to slow the progression of the disease, preclinical studies have demonstrated some neuroprotective effects of MAO-B blockers in animal experimental models. These drugs are generally well tolerated, although some concerns have been expressed with selegiline regarding cardiovascular effects ([@b23]).

Three recent level 1 studies have provided new data on MAO-B rationale for clinical use. In 473 untreated early PD patients allocated to treatment with dopamine agonists (bromocriptine and lisuride), or to selegiline ([@b7]), the authors found that the lower frequency of motor complications in patients assigned to selegiline was not statistically significant after a multivariate analysis including effects of age, disease duration, and baseline severity scores.

[@b50] performed an independent randomization of 368 patients from the DATATOP original cohort, who had been treated with selegiline and thereafter required levodopa, continuing with selegiline or switching to placebo under double-blind conditions. Patients were followed for 2 years, and primary outcome was the time to the first development of "wearing-off" "on-off" fluctuations, dyskinesia and freezing of gait; confusion and dementia were included in the analysis as well. The frequency of new occurrence in any primary variables was not significantly different between the two arms.

Rasagiline, a second-generation, selective, reversible MAO-B inhibitor, is associated with benefit in patients with early disease stage and reduced "off" time in patients with motor fluctuations ([@b36]). According to the TEMPO study ([@b41]), rasagiline is beneficial as monotherapy in the early stage of the disease. Similar benefit was reported in the LARGO study that compared the effect of entacapone and rasagiline in advanced PD ([@b46]). Interestingly, a significant mean reduction in "off" time was reported only in patients with mild to moderate dyskinesia but no advantage compared to placebo was found in the most severe advanced PD cohort. These findings confirm the difficulties that current strategies encounter in the management of this specific group of patients.

COMT inhibition with entacapone and tolcapone
---------------------------------------------

Association of DDCIs with levodopa increases its metabolism by catechol-O-methyltransferase to 3-O-methyl-dopa (3-OMD), in organs expressing COMT activity, such as liver, kidney, and gastrointestinal tract.

The 3-OMD metabolite has a long elimination half-life (approximately 15 hours), and may accumulate during long-term levodopa therapy. 3-OMD may compete with levodopa for passage across the BBB; moreover cerebral COMT metabolize levodopa to 3-OMD and dopamine to homovanillic acid ([@b19]). On the basis of this knowledge, the role of COMT inhibition seems crucial in PD therapy. Peripheral COMT inhibition reduces degradation of levodopa to 3-OMD, thus widening its therapeutic window, while a central COMT inhibition may further prolong levodopa effectiveness by reducing both levodopa and dopamine metabolism.

The new generation of COMT inhibitors entacapone and tolcapone are potent and selective and their role has become increasingly evident in the last decade ([Figure 1](#fig1){ref-type="fig"}).
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The two drugs show a number of pharmacologic differences and consequently, different clinical effectiveness. Tolcapone is a selective, reversible peripheral COMT inhibitor ([@b30]). Activity on central COMT has also been demonstrated both clinically and with functional imaging ([@b8]) and it can be observed for doses of 200 mg tid.

Data about efficacy and safety of these drugs have been examined recently by a Cochrane review ([@b12]). Comparing the efficacy of the two COMT inhibitors across 8 randomized controlled trials, tolcapone produced larger reductions in "off" time and levodopa requirements.

Tolerability profile was similar; some of the reported adverse events were related to the increased availability of levodopa (nausea, vomiting, dyskinesias, hallucination), and ameliorated reducing levodopa dose. Some other adverse events were more strictly related to COMT-inhibition, in particular the occurrence of diarrhea.

Role of tolcapone in PD management
==================================

Tolcapone, a potent selective reversible COMT inhibitor, was launched in Europe in 1997, and in the US in 1998 ([@b22]). Its efficacy as adjunct to levodopa therapy is attributed to the peripheral COMT inhibition, whereas there is still some debate around clinical relevance associated to the central activity. Results of clinical trials conducted in PD patients, confirm that tid administration of tolcapone magnifies levodopa motor benefit. Improvement had already been observed with a single 200 mg dose ([@b30]).

Compared with levodopa/DDCI alone, single or multiple doses of tolcapone 100 or 200 mg increased levodopa bioavailability by 1.3 to 2.1 fold, both in healthy volunteers and in PD patients ([@b25]).

Pharmacological profile of tolcapone is characterized by a greater bioavailability, and so has a greater area under the curve, T~max~ and COMT enzyme affinity, compared with entacapone. Tolcapone increases the levodopa half-life by 80% versus 40% for entacapone, the levodopa area under the curve by 80% versus 40% for entacapone, providing a greater decrease in the formation of O-methyl-dopa as well ([@b15]).

The results of a long-term comparative study between tolcapone and entacapone, suggest that tolcapone is more effective, and this difference in response would be predicted by the pharmacological differences between the two agents ([@b37]). The study, performed in patients with fluctuating PD, compared efficacy and tolerability of tolcapone and entacapone, evaluating the effects prospectively at 6, 12, 24, and 36 months. Fourteen patients were enrolled under tolcapone treatment, and eleven patients were enrolled under entacapone treatment. Tolcapone showed more effectiveness in lowering UPDRS motor score and complication subscores, duration of "off" periods, and levodopa doses requirement (UPDRS motor score change was −5.07 ± 1.48 in tolcapone group, and +2.46 ± 2.76 for entacapone (p \< 0.02); duration of "off" period was −1 ± 0.23 for tolcapone, 0 ± 0.27 for entacapone (p \< 0.03), lowering of L--DOPA dose was −400 ± 70.7 for tolcapone and +179.2 ± 160.8 for entacapone (p \< 0.04).

Another study in 40 patients with severe PD, with open design and direct switch-over from tolcapone to entacapone, was prompted because of mandatory indications of the European drugs authority, who withdrew tolcapone from market in November 1998. "On" time was increased by 15% during tolcapone treatment (p \< 0.05), and by 8% during entacapone treatment, whereas "off" time was decreased by 16% during tolcapone and by 7% during entacapone treatment. The reduction of L-DOPA was significantly improved by tolcapone compared with entacapone (p = 0.05) ([@b24]). IGA (Investigator Global Assessment) for wearing off severity, indicated that 70--73% of the patients receiving tolcapone, and 56% of patients receiving entacapone, had a relevant improvement (p = 0.01).

A recent double blind study assessed patients receiving entacapone after random assignement to continue entacapone (n = 75) or switch to tolcapone (n = 75). The "on" time increased by ≥1 hour day in 43% of entacapone patients and in 53% of tolcapone patients and by ≥3 hours day in 13% and 25% of patients, respectively. The IGA indicated moderate/marked improvement in 25% of entacapone patients and 39% receiving tolcapone. No differences were observed in the rate of dyskinesias and adverse events leading to discontinuation of treatment ([@b39]).

Safety and tolerability were evaluated with a focus on liver transaminase elevations and hepatotoxicity; 677 levodopa-naïve patients were randomized to receive placebo or tolcapone as add-on therapy to standard doses of levodopa ([@b52]). Liver transaminase elevations above the upper normal limit (ULN) occurred in 20.2% and 27.5% of patients in the placebo and tolcapone groups, respectively. Elevations of ULN ≥3 fold occurred in 1.2% and 1.8% of placebo and tolcapone patients, respectively. No serious hepatotoxicity events were reported.

Efficacy of oral tolcapone as adjunct therapy to levodopa/DDCI, was demonstrated in several trials, although only in the short period (3 weeks' to 3 months' duration), both in fluctuating and stable PD patients ([@b51]).

Clinical trials conducted in PD patients with motor fluctuations (wearing off, predictable "on-off"), were analyzed by a Committee of the American Academy of Neurology. The Committee recognized tolcapone is useful in reducing the "off" time, the need of levodopa daily dose, and prolonging the "on" phase.

Recently, also data from a comparator study (the SWITCH study) were presented. The aim of the study was to determine if switching from entacapone to tolcapone improves motor features. In the per-protocol analysis, a statistically significant greater proportion of patients switched to tolcapone, had at least 3 hours/day of additional "on" time (p = 0.018). More patients on tolcapone were judged to have a moderate or marked improvement in the IGA, although not statistically significant. Also the number of responders was higher on tolcapone, which appeared to have greater long-term benefits compared to entacapone ([Table 1](#tbl1){ref-type="table"}).

###### 

Efficacy of oral tolcapone 100 mg, entacapone, and rasagiline evaluated in terms of increasing hours of "on" time, decreasing hours of "off" time, and levodopa requirement

  Sudy          Study drug dosage (mg/tid)                     Study duration   N of patients   Mean change from baseline:                     Daily levodopa dosage:                                                                                                                             
  ------------- ---------------------------------------------- ---------------- --------------- ---------------------------------------------- ----------------------------------------------------------- -------------------------------------------------------------------------------------- ----------------------------------------
  [@b3]         Tolcapone 100                                  3 mo             60              +1.7 h[\*\*](#tf1-2){ref-type="table-fn"}      −2 h[\*](#tf1-1){ref-type="table-fn"}                       667.5                                                                                  −16[\*](#tf1-1){ref-type="table-fn"}
                Placebo                                                         58              −0.1 h                                         −0.7 h                                                      660.5                                                                                  −4
  [@b44]        Tolcapone 100                                  3 mo             69              --                                             −2.3 h                                                      788.5                                                                                  −21[\*\*](#tf1-2){ref-type="table-fn"}
                Placebo                                                         66                                                             −1.4 h                                                      948.0                                                                                  −2
  [@b1]         Tolcapone 100                                  6 wks            69              +2.1 h [\*\*\*](#tf1-3){ref-type="table-fn"}   −2.0 h[\*\*\*](#tf1-3){ref-type="table-fn"}                 810                                                                                    −23[\*\*](#tf1-2){ref-type="table-fn"}
                Placebo                                                         72                                                                                                                         850                                                                                    \>−1
  [@b49]        Tolcapone 100                                  6 wks            20              --                                             −15.8 %[\*](#tf1-1){ref-type="table-fn"}                    795.0                                                                                  −7
                Placebo                                                         20                                                             +1.2 %                                                      930.0                                                                                  −2
  SWITCH 2006   Tolcapone 100                                  3 wks            150 (tot)       +1.6[\*](#tf1-1){ref-type="table-fn"}          --                                                          --                                                                                     --
                Entacapone 200                                                                  +0.8                                                                                                                                                                                              
  [@b37]        Tolcapone 100                                  3--7 mo          40 (tot)        +15 %[\*](#tf1-1){ref-type="table-fn"}         −16 %                                                       Levodopa was significantly reduced with tolcapone: p = 0.01 and entacapone: p = 0.05   
                Entacapone 200                                                                  +8%                                            −7%                                                                                                                                                
  [@b46]        Rasagiline (1 mg/day)                          18 wks           231             +0.85 h                                        −1.18 h                                                                                                                                            
                Entacapone (200 mg/with every levodopa dose)                    200             +0.03 h                                        −1.2 h                                                                                                                                             
                Placebo                                                         229             (p = 0.0005 for both)                          −0.4 h (p = 0.0001, p \< 0.0001, respectively vs placebo)                                                                                          
  [@b42]        Rasagiline 0.5 mg/day                          26 wks           164             +0.51                                          −0.49                                                                                                                                              
                Rasagiline 1 mg/day                                             149             +0.78[\*](#tf1-1){ref-type="table-fn"}         −0.94[\*\*](#tf1-2){ref-type="table-fn"}                                                                                                           
                Placebo                                                         159                                                                                                                                                                                                               

p \< 0.05,

p \< 0.01,

p \< 0.001 vs placebo,

\*\*\*p = 0.018.

In patients with stable disease, tolcapone determines improvement from baseline in various end-points in a short-term study ([@b51]), showing an overall global improvement in 77% of patients at the IGA score, after 4 weeks double-blind treatment.

These preliminary results suggest potential benefit on both motor and non-motor fluctuations. In this respect, patient-perceived benefit, obtained by smoother levodopa response, might be regarded also as an indirect effect of improved non-motor fluctuations.

With regard to safety, dopaminergic-related adverse events were the most frequently reported in patients receiving 200 mg tolcapone tid. Such events (nausea, vomiting, dyskinesia, orthostatic complaints, sleep disorders, dystonia, confusion, hallucination), are likely a consequence of the increase in levodopa concentrations, especially at the beginning of treatment, and are mostly resolved with a reduction in levodopa dose. New or worsening dyskinesias were one of the most commonly reported dopaminergic-related adverse events (25%--62% with tolcapone, 100 mg 3 times daily, 31%--66% with 200 mg 3 times daily); in any case they were not a reason for withdrawal ([@b12]). Some major concerns have been raised in the past over the emergence of liver toxicity ([@b54]).

For this reason, marketing authorization for tolcapone was suspended in the EU (late 1998), and labeling was tightened in the US. However, suspension of the marketing authorization in the EU was later lifted following EMEA recommendation ([@b14]).

The cause of hepatotoxicity has not been clearly established yet, although the current hypothesis suggests a possible interference with mithocondrial respiration in hepathocytes, by uncoupling oxidative phosphorilation ([@b6]).

Three cases of fatal fulminant hepatic failure were reported with tolcapone in 1998, but it should be noted that liver function had not been properly monitored in these patients and that the liver dysfunction emerged 2--6 months after starting treatment ([@b34]). A recent review of tolcapone global safety (Valeant Pharmaceuticals International data on file), reported severe hepatocellular injury only in 0.04% of patients over the last 7 years, whereas the majority of patients experiencing liver toxicity, only showed an elevations in liver transaminases without clinical signs or symptoms.

In a review of clinical data on 1535 patients ([@b34]), the expert panel also noted that about half the patients who continued tolcapone therapy experienced a normalization of ALT/AST levels within 1--3 months, whereas patients who discontinued tolcapone experienced the normalization after just 2--3 weeks. These data are crucial in the evaluation of tolcapone's role in PD therapy; in fact, due to its fast onset of action, the identifications of responders can occur early, when the liver damage is probably still in a reversible initial phase, so non-responders may easily withdraw before liver damage is established, whereas responders should be strictly monitored, especially in the first 6 months.

In summary, tolcapone is a useful option for patients with idiopathic, fluctuating PD patients ([@b11]). Clinical practice suggests that tolcapone is more effective than entacapone and it can be successfully associated to levodopa preparations. In addition it has central activity with potential benefits on mood and cognition although this might be observed only at doses of 200 mg tid. Data on tolcapone effect in patients who have not benefited from entacapone (this would be the target population according to EMEA guidelines) are still lacking. Randomized trials are warranted to demonstrate that adding tolcapone in these individuals is indeed beneficial.

Conclusions
===========

Current evidence suggests that treatment strategies should target both motor and non-motor fluctuations, as the latter have been often neglected or underestimated in PD. COMT inhibitors are beneficial because they widen the therapeutic window in PD. In addition tolcapone may also have some central activity particularly at high dose. Given this evidence we suggest that tolcapone should be prescribed to all PD patients who continue to complain about motor fluctuations despite current or previous treatment with entacapone and/or MAO-B inhibitors. We believe that a tolcapone trial should be considered before other complex and more invasive procedures are proposed to the patient.
